Functional inhibitors of acid sphingomyelinase (FIASMAS): A novel pharmacological group of drugs with broad clinical applications

Cellular Physiology and Biochemistry

Volumn 26, Issue 1, 2010, Pages 9-20

  Kornhuber, Johannes ^a   Tripal, Philipp ^a   Reichel, Martin ^a   Mühle, Christiane ^a   Rhein, Cosima ^a   Muehlbacher, Markus ^a   Groemer, Teja W ^a   Gulbins, Erich ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acid ceramidase; Acid sphingomyelinase; Acid trapping; Cationic amphiphilic drugs; Desipramine; Lysosomotropism

Indexed keywords

AMLODIPINE; ASTEMIZOLE; BENZATROPINE; BEPRIDIL; CHLORPROTHIXENE; CLOMIFENE; CLOZAPINE; CYCLOBENZAPRINE; CYPROHEPTADINE; DIZOCILPINE; DOXEPIN; DROFENINE; FENDILINE; FLUOXETINE; MAPROTILINE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PIMETHIXENE; PROMAZINE; PROMETHAZINE; PROTRIPTYLINE; SERTRALINE; SPHINGOMYELIN PHOSPHODIESTERASE; SULOCTIDIL; TERFENADINE; TRIFLUPROMAZINE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; ENDOCYTOSIS; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIPID RAFT; LYSOSOME; MULTIPLE SCLEROSIS; NIEMANN PICK DISEASE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

EID: 77952908473     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315101     Document Type: Review

References (138)

1. Jin S, Yi F, Zhang F, Poklis JL, Li PL: Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:2056-2062.
2. Hannun YA, Luberto C: Ceramide in the eukaryotic stress response. Trends Cell Biol 2000;10:73-80.
3. Charruyer A, Grazide S, Bezombes C, Müller S, Laurent G, Jaffrézou JP: UV-C light induces raft-associated acid sphingo-myelinase and JNK activation and trans-location independently on a nuclear signal. J Biol Chem 2005;280:19196-19204.
4. Castillo SS, Levy M, Thaikoottathil J V, Goldkorn T: Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res 2007;313:2680-2686.
5. Santana P, Peña LA, Haimovitz-Fried-man A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z, Kolesnick R: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86:189-199.
6. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman EH, Kolesnick RN, Tilly JL: Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-1114.
7. Peña LA, Fuks Z, Kolesnick RN: Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000;60:321-327.
8. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R: En-dothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293:293-297.
9. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Fried-man A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by en-dothelial cell apoptosis. Science 2003;300:1155-1159.
10. Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001;276:20589-20596.
11. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E: Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330.
12. Yu ZF, Nikolova-Karakashian M, Zhou D, Cheng G, Schuchman EH, Mattson MP: Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci 2000;15:85-97.
13. Zhang Y, Mattjus P, Schmid PC, Dong Z, Zhong S, Ma W Y, Brown RE, Bode AM, Schmid HHO, Dong Z: Involvement of the acid sphingomyelinase pathway in UVA-induced apoptosis. J Biol Chem 2001;276:11775-11782.
14. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnick R, Altman A, Green D: FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 1995;2:341-351.
15. Chung HS, Park SR, Choi EK, Park HJ, Griffin RJ, Song CW, Park H: Role of sphingomyelin-MAPKs pathway in heat-induced apoptosis. Exp Mol Med 2003;35:181-188.
16. Kolesnick RN: 1,2-Diacylglycerols but not phorbol esters stimulate sphingomy-elin hydrolysis in GH3 pituitary cells. J Biol Chem 1987;262:16759-16762.
17. Megha, London E: Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): Implications for lipid raft structure and function. J Biol Chem 2004;279:9997-10004.
18. Nyberg L, Duan R-D, Axelson J, Nilsson A: Identification of an alkaline sphingomyelinase activity in human bile. Biochim Biophys Acta 1996;1300:42-48.
19. Liu B, Hassler DF, Smith GK, Weaver K, Hannun YA: Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain. J Biol Chem 1998;273:34472-34479.
20. Karakashian AA, Giltiay NV, Smith GM, Nikolova-Karakashian MN: Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-b-induced JNK activation. FASEB J 2004;18:968-970.
21. Kirschnek S, Paris F, Weller M, Grassmé H, Ferlinz K, Riehle A, Fuks Z, Kolesnick R, Gulbins E: CD95-mediated apoptosis in vivo involves acid sphingomyelinase. J Biol Chem 2000;275:27316-27323.
22. He X, Huang Y, Li B, Gong CX, Schuchman EH: Deregulation of sphin-golipid metabolism in Alzheimer's disease. Neurobiol Aging 2008.
23. Schuchman EH, Suchi M, Takahashi T, Sandhoff K, Desnick RJ: Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem 1991;266:8531-8539.
24. Qiu H, Edmunds T, Baker-Malcolm J, Karey KP, Estes S, Schwarz C, Hughes H, Van Patten SM: Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J Biol Chem 2003;278:32744-32752.
25. He X, Okino N, Dhami R, Dagan A, Gatt S, Schulze H, Sandhoff K, Schuchman EH: Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem 2003;278:32978-32986.
26. Schulze H, Schepers U, Sandhoff K: Overexpression and mass spectrometry analysis of mature human acid ceramidase. Biol Chem 2007;388:1333-1343.
27. Al BJM, Tiffany CW, Gomes de Mesquita DS, Moser HW, Tager JM, Schram AW: Properties of acid ceramidase from human spleen. Biochim Biophys Acta 1989;1004:245-251.
28. Bartelsen O, Lansmann S, Nettersheim M, Lemm T, Ferlinz K, Sandhoff K: Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification, processing and enzymatic characterization. J Biotechnol 1998;63:29-40.
29. Bernardo K, Hurwitz R, Zenk T, Desnick RJ, Ferlinz K, Schuchman EH, Sandhoff K: Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem 1995;270:11098-11102.
30. Lansmann S, Ferlinz K, Hurwitz R, Bartelsen O, Glombitza G, Sandhoff K: Purification of acid sphingomyelinase from human placenta: Characterization and N-terminal sequence. FEBS Lett 1996;399:227-231.
31. Linke T, Lansmann S, Sandhoff K: Purification of acid ceramidase from human placenta. Methods Enzymol 2000;311:201-207.
32. Quintern LE, Weitz G, Nehrkorn H, Tager JM, Schram AW, Sandhoff K: Acid sphingomyelinase from human urine: purification and characterization. Biochim Biophys Acta 1987;922:323-336.
33. Tayama M, Soeda S, Kishimoto Y, Martin BM, Callahan JW, Hiraiwa M, O'Brien JS: Effect of saposins on acid sphingomyelinase. Biochem J 1993;290:401-404.
34. Schwarz A, Futerman AH: Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J Neurosci 1997;17:2929-2938.
35. Futerman AH, Hannun YA: The complex life of simple sphingolipids. EMBO Rep 2004;5:777-782.
36. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, Milstien S, Spiegel S: Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-in-duced cell motility. Science 2001;291:1800-1803.
37. Spiegel S, Milstien S: Sphingosine 1-phos-phate, a key cell signaling molecule. J Biol Chem 2002;277:25851-25854.
38. Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstien S, Bigbee J W, Spiegel S: Differential transactivation of sphingosine-1-phos-phate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166:381-392.
39. Spiegel S, Merrill AH, Jr.: Sphingolipid metabolism and cell growth regulation. FASEB J 1996;10:1388-1397.
40. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-803.
41. Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera A, Pirianov G, Thomas DM, Tu Z, Van B, Jr., Wang F: Sphingosine-1-phosphate in cell growth and cell death. Ann N Y Acad Sci 1998;845:11-18.
42. Brady RO, Kanfer JN, Mock MB, Fredrickson DS: The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci USA 1966;55:366-369.
43. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang T-Y, Liscum L, Strauss JF, III, Ohno K, Zeigler M, Carmi R, Sokol J, Markie D, O'Neill RR, van Diggelen OP, Elleder M, Patterson MC, Brady RO, Vanier MT, Pentchev P G, Tagle DA: Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science 1997;277:228-231.
44. Schuchman EH, Miranda SRP: Niemann-Pick disease: Mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test 1997;1:13-19.
45. Uhlig S, Gulbins E: Sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-1114.
46. Smith EL, Schuchman EH: The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 2008;22:3419-3431.
47. Kolesnick R: The therapeutic potential of modulating the ceramide/sphingomy-elin pathway. J Clin Invest 2002;110:3-8.
48. Gulbins E, Li PL: Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 2006;290:R11-R26.
49. Thevissen K, François IEJA, Winderickx J, Pannecouque C, Cammue BPA: Ceramide involvement in apoptosis and apoptotic diseases. Mini Rev Med Chem 2006;6:699-709.
50. Deigner HP, Haberkorn U, Kinscherf R: Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs 2000;9:747-764.
51. Pandey S, Murphy RF, Agrawal DK: Recent advances in the immunobiology of ceramide. Exp Mol Pathol 2007;82:298-309.
52. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993;262:659-700.
53. Altura BM, Gebrewold A, Zheng T, Altura BT: Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke. Brain Res Bull 2002;58:271-278.
54. Pascual M, Valles SL, Renau-Piqueras J, Guerri C: Ceramide pathways modulate ethanol-induced cell death in astrocytes. J Neurochem 2003;87:1535-1545.
55. Reichel M, Greiner E, Richter-Schmidinger T, Yedibela Ö, Tripal P, Jacobi A, Bleich S, Gulbins E, Kornhuber J: Increased acid sphingomyelinase activity in peripheral blood cells of acutely intoxicated patients with alcohol dependence. Alcohol Clin Exp Res 2010;34:46-50.
56. Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T: Soluble oligomers of amyloid-b peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingo-myelinase-ceramide pathway. Neurobiol Dis 2006;23:178-189.
57. Han X, Holtzman M, McKeel DW, Jr., Kelley J, Morris JC: Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002;82:809-818.
58. Cuzzocrea S, Deigner H-P, Genovese T, Mazzon E, Esposito E, Crisafulli C, Di PR, Bramanti P, Matuschak G, Salvemini D: Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. Shock 2009;31:634-644.
59. Mikati MA, Zeinieh M, Habib RA, El HJ, Rahmeh A, El SM, Usta J, Dbaibo G: Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus. Epilepsy Res 2008;81:161-166.
60. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, Edwards CK, III, Schuchman EH, Fuks Z, Kolesnick R: Lipopolysac-charide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997;186:1831-1841.
61. Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Lösche W, Kinscherf R, Deigner H-P: Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 2005;19:1719-1721.
62. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
63. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, de Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassme H, Döring G, Gulbins E: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fi-brosis. Nat Med 2008;14:382-391.
64. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E: Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 2009;in press.
65. Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E: Therapeutic efficacy and safety of amitriptyl-ine in patients with cystic fibrosis. Cell Physiol Biochem 2009;24:65-72.
66. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S: Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 2007;122:54-64.
67. Bauer J, Liebisch G, Hofmann C, Huy C, Schmitz G, Obermeier F, Bock J: Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One 2009;4:e7197.
68. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze S, Gulbins E, Uhlig S: PAF-mediated pulmonary edema: a new role for acid sphingo-myelinase and ceramide. Nat Med 2004;10:155-160.
69. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM: Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005;11:491-498.
70. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E: High activity of acid sphingomyelinase in major depression. J Neural Transm 2005;112:1583-1590.
71. Kornhuber J, Reichel M, Tripal P, Groemer TW, Henkel AW, Mühle C, Gulbins E: The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2009;259:S199-S204.
72. Ndengele MN, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM, Salvemini D: Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 2009;329:64-75.
73. Grassmé H, Gulbins E, Brenner B, Ferlinz K, Sandhoff K, Harzer K, Lang F, Meyer TF: Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 1997;91:605-615.
74. Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I: Acid sphingomyelinase promotes lipo-protein retention within early athero-mata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008;28:1723-1730.
75. Augé N, Nègre-Salvayre A, Salvayre R, Levade T: Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 2000;39:207-229.
76. Marathe S, Kuriakose G, Williams KJ, Tabas I: Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler Thromb Vasc Biol 1999;19:2648-2658.
77. Kornhuber J, Retz W, Riederer P: Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm Suppl 1995;46:311-319.
78. Mintzer RJ, Appell KC, Cole A, Johns A, Pagila R, Polokoff MA, Tabas I, Snider RM, Meurer-Ogden JA: A novel high-throughput screening format to identify inhibitors of secreted acid sphingo-myelinase. J Biomol Screen 2005;10:225-234.
79. Testai FD, Landek MA, Goswami R, Ahmed M, Dawson G: Acid sphingo-myelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oli-godendrocyte cell signaling. J Neurochem 2004;89:636-644.
80. Kölzer M, Arenz C, Ferlinz K, Werth N, Schulze H, Klingenstein R, Sandhoff K: Phosphatidylinositol-3,5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol Chem 2003;384:1293-1298.
81. Okudaira C, Ikeda Y, Kondo S, Furuya S, Hirabayashi Y, Koyano T, Saito Y, Umezawa K: Inhibition of acidic sphingomyelinase by xanthone compounds isolated from Garcinia speciosa. J Enzyme Inhib 2000;15:129-138.
82. Hamada M, Iikubo K, Ishikawa Y, Ikeda A, Umezawa K, Nishiyama S: Biological activities of alpha-mangostin derivatives against acidic sphingomyelinase. Bioorg Med Chem Lett 2003;13:3151-3153.
83. Darroch PI, Dagan A, Granot T, He X, Gatt S, Schuchman EH: A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death. J Lipid Res 2005;46:2315-2324.
84. Roth A G, Redmer S, Arenz C: Potent inhibition of acid sphingomyelinase by phosphoinositide analogues. Chembiochem 2009;10:2367-2374.
85. Roth A G, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C: Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed Engl 2009;48:7560-7563.
86. Albouz S, Hauw JJ, Berwald-Netter Y, Boutry JM, Bourdon R, Baumann N: Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedi-cine 1981;35:218-220.
87. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E: Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem (Tokyo) 1985;98:1669-1679. (Pubitemid 16169203)
88. Sakuragawa N, Sakuragawa M, Kuwabara T, Pentchev PG, Barranger JA, Brady RO: Niemann-Pick disease experimental model: sphingomyelinase reduction induced by AY-9944. Science 1977;196:317-319.
89. Kölzer M, Werth N, Sandhoff K: Interactions of acid sphingomyelinase and li-pid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 2004;559:96-98.
90. Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressants desipramine causes proteolytic degradation of lyso-somal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 1994;375:447-450.
91. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E: Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008;51:219-237.
92. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH, Hannun YA, Bielawska A, Norris JS: Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008;61:231-242.
93. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong J-Y, El-Zawahry AM, Guo G-W, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS: Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 2008;13:2293-2298.
94. Zeidan YH, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS, Hannun YA: Molecular targeting of acid ceramidase: Implications to cancer therapy. Curr Drug Targets 2008;9:653-661.
95. Grijalvo S, Bedia C, Triola G, Casas J, Llebaria A, Teixidó J, Rabal O, Levade T, Delgado A, Fabriàs G: Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues. Chem Phys Lipids 2006;144:69-84.
96. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Rembiesa B, Pierce J, Norris JS, Hannun YA: Novel analogs of D-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids. Bioorg Med Chem 2008;16:1032-1045. (Pubitemid 351163040)
97. Sugita M, Willians M, Dulaney JT, Moser HW: Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta 1975;398:125-131.
98. Bedia C, Casas J, Garcia V, Levade T, Fabriàs G: Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 2007;8:642-648.
99. Bedia C, Canals D, Matabosch X, Harrak Y, Casas J, Llebaria A, Delgado A, Fabriás G: Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Phys Lipids 2008;156:33-40.
100. Nahas Z, Jiang Y, Zeidan YH, Bielawska A, Szulc Z, Devane L, Kalivas P, Hannun YA: Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats. Behav Brain Res 2009;197:41-44.
101. Linke T, Wilkening G, Sadeghlar F, Mozcall H, Bernardo K, Schuchman E, Sandhoff K: Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J Biol Chem 2001;276:5760-5768.
102. Linke T, Wilkening G, Lansmann S, Moczall H, Bartelsen O, Weisgerber J, Sandhoff K: Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol Chem 2001;382:283-290.
103. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA, Norris JS: New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 2006;580:4751-4756.
104. Matter H: Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J Med Chem 1997;40:1219-1229.
105. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings. Adv Drug Deliv Rev 1997;23:3-25.
106. Trapp S, Rosania GR, Horobin RW, Kornhuber J: Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 2008;37:1317-1328.
107. Kornhuber J, Reichel M, Tripal P, Groemer TW, Henkel AW, Mühle C, Gulbins E: The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2009;259:S199-S204.
108. Lombardo F, Obach RS, Shalaeva MY, Gao F: Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem 2004;47:1242-1250.
109. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C: Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 2009;28:1043-1054.
110. Brand V, Koka S, Lang C, Jendrossek V, Huber SM, Gulbins E, Lang F: Influence of amitriptyline on eryptosis, parasitemia and survival of Plasmodium berghei-infected mice. Cell Physiol Biochem 2008;22:405-412.
111. Grassmé H, Riehle A, Wilker B, Gulbins E: Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J Biol Chem 2005;280:26256-26262.
112. Bauer J, Huy C, Brenmoehl J, Obermeier F, Bock J: Matrix metalloproteinase-1 expression induced by IL-1b requires acid sphingomyelinase. FEBS Lett 2009;583:915-920.
113. Llacuna L, Marí M, Garcia-Ruiz C, Fernandez-Checa JC, Morales A: Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 2006;44:561-572.
114. Kato Y, Ozawa S, Tsukuda M, Kubota E, Miyazaki K, St-Pierre Y, Hata R: Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J 2007;274:3171-3183.
115. Deigner H-P, Claus R, Bonaterra GA, Gehrke C, Bibak N, Blaess M, Cantz M, Metz J, Kinscherf R: Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. FASEB J 2001;15:807-814.
116. Lübke T, Lobel P, Sleat DE: Proteomics of the lysosome. Biochim Biophys Acta 2009;1793:625-635.
117. The selection and use of essential medicines. World Health Organ Tech Rep Ser 2004;920:1-127.
118. The WHO Collaborating Centre for Drug Statistics Methodology NIoPH. The ATC/DDD System. http://www.whocc.no/atcddd/
119. Approved Drug Products with Therapeutic Equivalence Evaluations, ed 28th edition. U.S. Department of Health and Human Servies. Food and Drug Administration. Center for Drug Evaluation and Research. Office of Pharmaceutical Science. Office of Generic Drugs, 2008.
120. Micro Source Discovery. Pure Natural Products. www.msdiscovery.com/ natprod.html
121. Anderson N, Borlak J: Drug-induced phospholipidosis. FEBS Lett 2006;580:5533-5540.
122. Lüllmann-Rauch R: Drug-induced lyso-somal storage disorders. Front Biol 1979;48:49-130.
123. Xia Z, Ying G, Hansson AL, Karlsson H, Xie Y, Bergstrand A, DePierre JW, Nässberger L: Antidepressant-induced li-pidosis with special reference to tricyclic compounds. Prog Neurobiol 2000;60:501-512.
124. Reasor MJ, Kacew S: Drug-induced phospholipidosis: Are there functional consequences? Exp Biol Med (Maywood) 2001;226:825-830.
125. Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical anti-psychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
126. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
127. Kornhuber J, Weller M: Psycho-togenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135-144.
128. Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG: Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neural Transm 1999;106:857-867.
129. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J: Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008;79:1027-1031.
130. Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J.: Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res: Neuroimaging 2008;164:274-282.
131. Flax JW, Gray J, Herbert J: Effect of fluoxetine on patients with multiple sclerosis. Am J Psychiatry 1991;148:1603.
132. Albouz S, Boutry JM, Dubois G, Bourdon R, Hauw JJ, Baumann N: Lipid and lyso-somal enzymes in human fibroblasts cultured with perhexiline maleate. Naunyn Schmiedebergs Arch Pharmacol 1981;317:173-177.
133. Kubo M, Hostetler KY: Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry 1985;24:6515-6520.
134. Matsuzawa Y, Hostetler KY: Inhibition of lysosomal phospholipase A and phos-pholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy)α,β- diethyldiphenylethane. J Biol Chem 1980;255:5190-5194.
135. Hostetler KY, Matsuzawa Y: Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem Pharmacol 1981;30:1121-1126.
136. Jaffrézou JP, Herbert JM, Levade T, Gau MN, Chatelain P, Laurent G: Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. J Biol Chem 1991;266:19858-19864.
137. Albouz S, Vanier MT, Hauw JJ, Le Saux F, Boutry JM, Baumann N: Effect of tricyclic antidepressants on sphingo-myelinase and other sphingolipid hydrolases in C6 cultured glioma cells. Neurosci Lett 1983;36:311-315.
138. Igarashi M, Suzuki K, Chen SM: Changes in brain hydrolytic enzyme activities in rats treated with cholesterol biosynthesis inhibitor, AY9944. Brain Res 1975;90:97-114.